跳到正文

法规知识库 · EMA 集中审评

Beyfortus

nirsevimab · EMEA/H/C/005304 · 已授权

PRIME额外监测

获批上市许可

2022-10-31

欧委会决定日

2026-03-12

持有人 / 申请人

Sanofi Winthrop Industrie

终止日期字段

无

从产品到官方文件

文件记录

12

官方索引 12

EPAR / 审评

9

assessment / overview 等

产品信息

3

PI / presentations

其他

0

RMP / PIP 等

ATC:J06BD08

治疗领域:—

药理分类:Immune sera and immunoglobulins

修订号:15 · 最新影响 PI 的程序:VR/0000319983

适应症(原文):Beyfortus is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in:i. Neonates and infants during their first RSV season.ii. Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season (see section 5.1).Beyfortus should be used in accordance with official recommendations. Beyfortus is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in:i. Neonates and infants during their first RSV season.ii. Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season (see section 5.1).Beyfortus should be used in accordance with official recommendations.

关键日期时间轴

来自 EMA medicines JSON 日期字段;缺失字段不展示,不补推结论。

  1. 2026-03-12 · 欧委会决定

  2. 2022-10-31 · 获批上市许可

  3. 2022-09-15 · CHMP 意见通过

说明书、EPAR 与其他文件

仅展示 EMA 官方 document_url;本站不下载或镜像 PDF。

EPAR / 审评资料 9产品信息 3其他 0

EPAR / 审评资料

  • Beyfortus-PAM-0000303330 : EPAR - Assessment report

    variation-report · 2026-04-24 · EMADOC-1700519818-2500371

    打开官方文件 ↗
  • Beyfortus : EPAR - Procedural steps taken and scientific information after authorisation

    procedural-steps-after · 2026-04-01

    打开官方文件 ↗
  • Beyfortus : EPAR - Procedural steps taken and scientific information after authorisation (archive)

    procedural-steps-after · 2025-06-24

    打开官方文件 ↗
  • Beyfortus : EPAR - Risk management plan

    rmp · 2024-10-07

    打开官方文件 ↗
  • Beyfortus-H-C-005304-II-0005 : EPAR - Assessment report - Variation

    variation-report · 2024-09-24 · EMA/355992/2024

    打开官方文件 ↗
  • Beyfortus : EPAR - Medicine Overview

    overview · 2024-09-04 · EMA/776857/2022

    打开官方文件 ↗
  • Beyfortus : EPAR - Statement indicating compliance with the agreed completed paediatric investigation plan

    pip-compliance · 2024-06-05 · EMA/182502/2024

    打开官方文件 ↗
  • Beyfortus-H-C-005304-P46-006 : EPAR - Assessment Report

    variation-report · 2024-01-15

    打开官方文件 ↗
  • Beyfortus : EPAR - Public assessment report

    assessment-report · 2022-11-15 · EMA/786523/2022

    打开官方文件 ↗

产品信息

  • Beyfortus : EPAR - Product Information

    product-information · 2026-04-01

    打开官方文件 ↗
  • Beyfortus : EPAR – Product information - tracked changes

    product-information-tracked-changes · 2025-06-17

    打开官方文件 ↗
  • Beyfortus : EPAR - All authorised presentations

    all-authorised-presentations · 2022-11-15

    打开官方文件 ↗

数据来自 EMA 官方 JSON;最终以 EMA / 欧委会文件为准。本页不自动给出安全或非安全结论。